Facioscapulohumeral Muscular Dystrophy clinical trials

Explore recruiting facioscapulohumeral muscular dystrophy clinical trials.

Recruiting facioscapulohumeral muscular dystrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Facioscapulohumeral Muscular Dystrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Netherlands, Spain, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Netherlands, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Italy, Spain, France, Germany, Netherlands, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Italy, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with Extension

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A bicentric, randomized, double blind, placebo-controlled pilot study to evaluate the efficacy and safety of satralizumab in FSHD1

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Facioscapulohumeral Muscular Dystrophy trials by city

Facioscapulohumeral Muscular Dystrophy in Toronto Facioscapulohumeral Muscular Dystrophy in Vancouver Facioscapulohumeral Muscular Dystrophy in Montreal Facioscapulohumeral Muscular Dystrophy in Calgary Facioscapulohumeral Muscular Dystrophy in Edmonton Facioscapulohumeral Muscular Dystrophy in Ottawa Facioscapulohumeral Muscular Dystrophy in Winnipeg Facioscapulohumeral Muscular Dystrophy in Quebec City Facioscapulohumeral Muscular Dystrophy in Hamilton Facioscapulohumeral Muscular Dystrophy in Kitchener Facioscapulohumeral Muscular Dystrophy in London Facioscapulohumeral Muscular Dystrophy in Halifax Facioscapulohumeral Muscular Dystrophy in New York Facioscapulohumeral Muscular Dystrophy in Los Angeles Facioscapulohumeral Muscular Dystrophy in Chicago Facioscapulohumeral Muscular Dystrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease